Publikationsdatum:
2017-11-21
Beschreibung:
Prostaglandin E 2 (PGE 2 ) increases cell proliferation and stimulates migratory and angiogenic abilities in prostate cancer cells. However, the effects of PGE 2 on non-transformed prostate epithelial cells are unknown, despite the fact that PGE 2 overproduction has been found in benign hyperplastic prostates. In the present work we studied the effects of PGE 2 in immortalized, non-malignant prostate epithelial RWPE-1 cells and found that PGE 2 increased cell proliferation, cell migration, and production of vascular endothelial growth factor-A, and activated in vitro angiogenesis. These actions involved a non-canonic intracrine mechanism in which the actual effector was intracellular PGE 2 (iPGE 2 ) instead of extracellular PGE 2 : inhibition of the prostaglandin uptake transporter (PGT) or antagonism of EP receptors prevented the effects of PGE 2 , which indicated that PGE 2 activity depended on its carrier-mediated translocation from the outside to the inside of cells and that EP receptors located intracellularly (iEP) mediated the effects of PGE 2 . iPGE 2 acted through transactivation of epidermal growth factor-receptor (EGFR) by iEP, leading to increased expression and activity of hypoxia-inducible factor-1α (HIF-1α). Interestingly, iPGE 2 also mediates the effects of PGE 2 on prostate cancer PC3 cells through the axis iPGE 2 -iEP receptors-EGFR-HIF-1α. Thus, this axis might be responsible for the growth-stimulating effects of PGE 2 on prostate epithelial cells, thereby contributing to prostate proliferative diseases associated with chronic inflammation. Since this PGT-dependent non-canonic intracrine mechanism of PGE 2 action operates in both benign and malignant prostate epithelial cells, PGT inhibitors should be tested as a novel therapeutic modality to treat prostate proliferative disease. In this contribution we have found in immortalized, non-malignant prostate epithelial RWPE-1 cells that PGE2, through the axis intracellular PGE2-iEP receptors-EGFR-HIF-1α, inhibits cell adhesion and stimulates cell proliferation, migration and in vitro angiogenesis (i.e., the same effects than we have previously described in PC3 cells). Since intracellular PGE2 mediates the growth-stimulating effects of PGE2 on prostate epithelial cells, regardless they are benign or malign ones, the pharmacological inhibition of the prostaglandin trasnporter PGT could be a novel therapeutic approach to treat prostate proliferative diseases associated with chronic inflammation.
Digitale ISSN:
1097-4652
Thema:
Biologie
,
Medizin
Permalink